Stilla Technologies
Stilla Technologies was a Paris-based digital PCR company developing all-in-one nucleic acid quantification platforms (naica, Nio, Nio+) for life science research, pharmaceutical, and clinical diagnostics customers, acquired by Bio-Rad Laboratories in 2025.
- Company typePrivate
- Founded2013
- HeadquartersVillejuif, France
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stilla Technologies does
Stilla Technologies was a Paris-based (Villejuif, France) biotechnology company founded in 2013 that developed digital PCR (dPCR) platforms for absolute nucleic acid quantification. The company's core technology addressed key limitations of traditional quantitative PCR (qPCR), including the need for standard curves, limited precision at low copy numbers, and constrained multiplexing, by partitioning samples into thousands of individual reactions for absolute target counting. Its products served life science research institutions, pharmaceutical companies (with applications in cell therapy, oncology, and infectious disease testing), and clinical diagnostics laboratories requiring highly sensitive and precise nucleic acid measurement.
The product portfolio centered on three platforms: the naica System (an all-in-one dPCR workflow integrating sample-to-result), the legacy Nio System, and the next-generation Nio+ instrument launched in 2024 with high multiplexing capabilities enabling multi-target detection in a single reaction. The company held registered trademarks for "Stilla," "naica," and "Nio," and its underlying technology was supported by an installed base cited in over 12,000 peer-reviewed publications. Revenue derived from instrument sales combined with recurring consumables including proprietary cartridges, supermixes, reagents, and assay kits, distributed through direct enterprise sales and, post-acquisition, Bio-Rad's global commercial channels.
Stilla pursued a sales-led go-to-market targeting academic research, pharmaceutical, and clinical diagnostics customers, raising approximately €57.8 million in cumulative venture funding across rounds led by investors including Casdin Capital, the European Investment Bank, Tusholdings, Illumina Ventures, Kurma Partners, and CLIIF. In February 2025 the company was acquired by Bio-Rad Laboratories (NYSE: BIO) with the transaction completing in June 2025; following the deal, Stilla's platforms are integrated into Bio-Rad's Droplet Digital PCR portfolio alongside the expanded QX ddPCR instrument family, and Bio-Rad has guided that the acquisition will be accretive by mid-2026, six to 12 months earlier than initially anticipated.
Stilla Technologies firmographics
Firmographics- Name
- Stilla Technologies
- Website
- https://stillatechnologies.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Stilla Technologies was a Paris-based digital PCR company developing all-in-one nucleic acid quantification platforms (naica, Nio, Nio+) for life science research, pharmaceutical, and clinical diagnostics customers, acquired by Bio-Rad Laboratories in 2025.
- Ownership category
- akta.pro rank
Stilla Technologies industry classification
Industry- Product category
- Digital PCR Instruments and Molecular Diagnostics Platforms
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
Keywords
Where Stilla Technologies is headquartered
LocationHeadquarters
- HQ city
- Villejuif
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Stilla Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Digital PCR Instruments and Consumables: Stilla Technologies generated revenue from the sale of digital PCR instruments (Nio+, naica, Nio systems) and associated consumables including cartridges, reagents, and assays. Following acquisition by Bio-Rad in 2025, this revenue stream is now integrated into Bio-Rad's Life Science segment which reported Q4 2025 revenue of $267.9 million for the Life Science segment.
- Digital PCR Reagents and Assays: Sale of specialized reagents, supermixes, and assay kits designed for use with Stilla's digital PCR platforms. These consumable products provide recurring revenue tied to instrument utilization.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Stilla Technologies product offering
Product offeringCore offering
Stilla Technologies develops and manufactures digital PCR (dPCR) instruments—the naica System, Nio System, and the next-generation Nio+—along with associated consumables including cartridges, reagents, supermixes, and assay kits. These platforms deliver absolute nucleic acid quantification without standard curves and support high-multiplexing detection for molecular diagnostics, oncology, infectious disease testing, and cell therapy applications. Following Bio-Rad Laboratories' acquisition completed in June 2025, the products are sold through Bio-Rad's global commercial organization.
Product overview
Stilla Technologies developed a portfolio of all-in-one digital PCR platforms, including the naica System, Nio System, and the newer Nio+ instrument. The Nio+ represents the next-generation platform featuring high multiplexing capabilities for enhanced molecular diagnostics applications. The company was acquired by Bio-Rad Laboratories in February 2025, with the acquisition completed in June 2025, integrating Stilla's digital PCR technology into Bio-Rad's Droplet Digital PCR (ddPCR) portfolio to accelerate innovation in molecular diagnostics for infectious disease testing, oncology, and cell therapy applications.
Differentiator
Problem solved
Functional benefit
Brands
- naica System: Legacy digital PCR system now part of Bio-Rad's portfolio following acquisition
- Nio System
Products and services
- naica System All-in-one digital PCR platform providing absolute quantification without the need for standard curves, with seamless workflow integration from sample to results. Targeted at molecular diagnostics applications including infectious disease testing, oncology, and liquid biopsy for research and clinical laboratories.
- Nio System Legacy digital PCR system originally developed by Stilla Technologies and now maintained as part of Bio-Rad's portfolio. Provides digital PCR capabilities for research and clinical applications.
- Nio+ Instrument Advanced next-generation digital PCR instrument featuring high multiplexing capabilities for multi-target detection in a single reaction. Designed for molecular diagnostics applications including infectious disease testing, oncology research, and cell therapy development for pharmaceutical companies, research institutions, and clinical diagnostics laboratories.
- Digital PCR Reagents and Consumables Specialized reagents, supermixes, droplet generation oil, cartridges, gaskets, plates, seals, and assay kits designed for use with Stilla's digital PCR platforms (naica and Nio systems). These consumables generate recurring revenue tied to instrument utilization and are used by life science researchers and clinical diagnostics laboratories.
Quantifiable outcome
- Droplet Digital PCR business showed strong growth in Q4 2025 following Stilla acquisition (Bio-Rad Q4 2025 earnings)
- +1 more outcomes
Companies that use Stilla Technologies
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles3 records
Stilla Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Stilla Technologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bio-Rad LaboratoriescoreBio-Rad Laboratories acquired Stilla Technologies in February 2025 to integrate Stilla's all-in-one digital PCR platforms (naica and Nio systems) into Bio-Rad's portfolio for accelerated innovation in molecular diagnostics for infectious disease testing, oncology, and cell therapy applications. Acquisition completed June 2025.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Stilla Technologies competitors and assessment
Company assessmentBroad incumbents
- Bio-Rad Laboratories: Parent company and the dominant player in digital PCR via its QX Droplet Digital PCR (ddPCR) platform. Acquired Stilla in 2025 and now distributes both Stilla's naica/Nio+ systems and its own QX ddPCR instruments, making it the most direct strategic peer.
- Thermo Fisher Scientific: Global life sciences incumbent offering the QuantStudio Absolute Q Digital PCR System alongside a broad molecular biology portfolio. Competes with Stilla in research and pharma labs and has substantially greater commercial reach.
- Roche Diagnostics: Major diagnostics player with digital PCR investments and a broad molecular diagnostics menu spanning infectious disease and oncology — the same high-value dPCR use cases Stilla targeted.
- Becton, Dickinson and Company (BD): Large diagnostics and life sciences company with molecular testing solutions including digital PCR-adjacent workflows in infectious disease and oncology — overlapping end-user segments with Stilla's clinical customers.
- PerkinElmer / Revvity: Offers reagents, consumables, and instruments used across genomic and molecular workflows, competing with Stilla for pharma and translational research budgets in nucleic acid quantification.
- Danaher (Cepheid, Beckman Coulter): Multi-brand life sciences conglomerate whose subsidiaries compete across molecular diagnostics and lab instrumentation; Cepheid's GeneXpert and adjacent platforms address overlapping clinical molecular use cases as Stilla's naica.
Direct peers
- QIAGEN: Direct digital PCR competitor through its QIAcuity dPCR platform, serving molecular diagnostics, research, and pharma customers with a fully integrated nanoplate-based system that competes head-to-head with Stilla's naica and Nio+.
- Standard BioTools: Operates the Biomark HD high-throughput real-time PCR system and microfluidics-based molecular workflows, competing for high-multiplex and translational research budgets that overlap with Stilla's Nio+ positioning.
- Promega Corporation: Provides nucleic acid analysis reagents and instruments, including quantification and detection solutions for research and clinical labs — overlapping product categories with Stilla's reagent/consumables line.
Emerging players
- Takara Bio: Specialized in molecular biology reagents and instrumentation, including digital PCR-adjacent technologies and gene therapy QC workflows that overlap with Stilla's cell therapy and gene expression use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Stilla Technologies social profiles
Digital presenceStilla Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stilla Technologies leadership team
Management profileNumber of profiles
Profiles8 records
Stilla Technologies funding detail
Funding detailFunding overview
Funding rounds6 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stilla Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stilla Technologies
What does Stilla Technologies do?
Stilla Technologies develops and manufactures digital PCR (dPCR) instruments—the naica System, Nio System, and the next-generation Nio+—along with associated consumables including cartridges, reagents, supermixes, and assay kits. These platforms deliver absolute nucleic acid quantification without standard curves and support high-multiplexing detection for molecular diagnostics, oncology, infectious disease testing, and cell therapy applications. Following Bio-Rad Laboratories' acquisition completed in June 2025, the products are sold through Bio-Rad's global commercial organization.
Is Stilla Technologies a public or private company?
Stilla Technologies is a private company. It is classified as corporate owned and is currently acquired.
When was Stilla Technologies founded?
Stilla Technologies was founded in 2013. It employs 51 to 100 people.
Where is Stilla Technologies based?
Stilla Technologies is headquartered in Villejuif, France, in the Europe region.
How does Stilla Technologies make money?
Two revenue lines are on record. Digital PCR Instruments and Consumables are the primary driver. The others are digital PCR Reagents and Assays.
Who are Stilla Technologies's main competitors?
Broad incumbents on record are Bio-Rad Laboratories, Thermo Fisher Scientific, Roche Diagnostics, Becton, Dickinson and Company (BD), PerkinElmer / Revvity and Danaher (Cepheid, Beckman Coulter). Direct peers are QIAGEN, Standard BioTools and Promega Corporation. Takara Bio is listed as an emerging player.
Does Stilla Technologies have an API?
No public API is recorded for Stilla Technologies.
What industry is Stilla Technologies in?
Stilla Technologies's product category is Digital PCR Instruments and Molecular Diagnostics Platforms. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 334516 and its SIC code is 3826.